ABSTRACT
Prostate cancer is a uniquely challenging disease. At the heart of the challenge is the disparity between the mortality rate (around 17.9 deaths per 100 000 men per annum in the UK, and 15.8 per 100 000 men per annum in the USA) and the incidence of the disease (around 52.2 cases per 100 000 in the UK, and 124.8 per 100 000 per annum in the USA).1
